Conclusion: Our data suggest that HGF and HPC may act synergistic

Conclusion: Our data suggest that HGF and HPC may act synergistically in inhibiting the toxicant-induced liver fibrosis in rats.

Therefore, the HGF-expressing fetal HPC may be used as a new therapeutic approach for the treatment of liver fibrosis. Key Word(s): 1. Hepatic fibrosis; Selleckchem BI 6727 2. fetal hepatic cells; 3. HGF; 4. gene therapy; Presenting Author: YINGDI LIU Additional Authors: YUNSHENG YANG, GUOJUN CHAI, GUOHUI SUN, HUA JIANG, JUAN WANG Corresponding Author: YINGDI LIU Affiliations: Chinese PLA General Hospital Objective: To evaluate the hemostatic effects of emergent endoscopic variceal sclerotherapy(EIS) combined with acrylate glue (N-butyl-2-cyanoacrylate, NBCA) injection (ESCI) on esophageal variceal bleeding, and to investigate glue extrusion after endoscopic injection. Methods: Thirty patients with esophageal variceal bleeding which failed in EIS before combined with NBCA injection were consecutively observed in the past 10 years. The clinical characteristics of patients, and hemostasis rate of ESCI were

observed, which compared the success rate of hemostasis and blood transfusion with the same period of 16 patients who were performed intervention treatment after failed in endoscopic therapy, hemostatic effect of ESCI, glue extrusion time and complications were analyzed. Results: A total of 30 patients with esophageal CP-673451 clinical trial variceal bleeding were recruited in our study (20:10 males/females) and 31 times of ESCI therapy were conducted, including 30 cases of successful therapy. No heterotopic embolism or serious infection was recorded. Transient fever was found in 6 cases and dysphagia was turned out

in 9 cases, sever dysphagia was found in 2 of them and released by endoscopic treatment afterwards. NBCA (1∼4 vials, mean 2.03 ± 0.182 vials) were injected into esophageal varices and glue extrusion from varices mainly started from 2 weeks (9 cases, 36.00%) to 3 weeks (15 cases, 60.00%) after the injection, mainly completed at week 2∼4 (88%). In comparison to 16 cases failed in endoscopic sclerotherapy, hemostasis Amisulpride were abtained with balloon tamponade during the same period, no significant difference was found with respect to hemostatic success rate, but the unit of blood transfusion and hospitalization costs were reduced. Twenty five cases were followed up for 12 months to 36 months, the average time was 20.23 ± 19.77 months. For one patient who was performed TIPSS after failed in endoscopic therapy, no rebleeding occurred in the following 30 months years. One patient with congenital hepatic arterioportal fistula died of massive upper gastrointestinal bleeding 2 months after treatment. Three patients with hepatocellular carcinoma died of liver failure 3∼7 months after the operation respectively. EV recurred within 6 months and 12 months after the operation in 4 and 2 cases respectively.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>